Search
Berdazimer
go.drugbank.com/drugs/DB18712ApprovedThis decision is based on positive results demonstrated in 2 Phase 3 trials, B-SIMPLE 4 and B-SIMPLE 2, where reduced lesion counts were observed with once-a-day uses of berdazimer.[L49520] … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.
Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnHowever, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.
Categories: Dopamine D2 Receptor AntagonistsMuromonab
go.drugbank.com/drugs/DB00075ApprovedInvestigationalWithdrawnMuromonab is 93% monomeric immune globulin G type 2a (IgG2a). … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.
Alogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalFDA approved January 25, 2013. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells. … Ziftomenib is a potent and highly selective menin inhibitor.
Synonyms: (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile, (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1Hindole-2-carbonitrileTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigationalto be approved by the FDA. … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalResorcinol is a 1,3-isomer (or meta-isomer) of benzenediol with the formula C6H4(OH)2. … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Mixtures: DG Health Feminine Anti-itchDextran
go.drugbank.com/drugs/DB09255ApprovedInvestigationalVet approvedDextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links.
Mixtures: DG Health Sterile Advanced Relief Eye, DG Health Advanced Relief Eye DropsCategories: Compounds used in a research, industrial, or household settingNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … effect compared to nandrolone and other esters.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates